Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature.

Michinori Funato, Toshiyuki Fukao, Hideo Sasai, Tomohiro Hori, Daisuke Terazawa, Kaori Kanda, Michio Ozeki, Keisuke Mizuta, Yoshinobu Hirose, Hideo Kaneko, Naomi Kondo

Journal: Head & neck 2014;35(8):E258-61

PMID: 22907922

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

BACKGROUND

Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed.

METHODS AND RESULTS

We describe an 11-year-old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel-based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory.

CONCLUSIONS

Paclitaxel-based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies.

Address: Department of Pediatrics, Gifu University, Gifu, Japan. [email protected]

DOI: 10.1002/hed.23107

Link outs

Free resources

Medical:

https://medlineplus.gov/headandneckcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Phytogenic, Child, Head and Neck Neoplasms, Hemangioendothelioma, Humans, Kasabach-Merritt Syndrome, Lung Neoplasms, Male, Paclitaxel, Sarcoma, Kaposi